OTLK
Outlook Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.67
−1.37%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -29.0%
- EBIT
- +23.4%
- EPS
- -83.3%
- Free cash flow
- -1.2%
- Operating cash flow
- -1.2%
Forward estimates
Based on analyst estimates
- Revenue
- +2519.6%
- EBITDA
- +90.9%
- EPS
- +88.1%
Three-year CAGR
- Revenue
- —
- EBITDA
- +11.8%
- EBIT
- +6.5%
- Net income
- +17.2%
- EPS
- +55.9%
- Free cash flow
- +24.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026